Title : Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells.

Pub. Date : 2020 Sep 1

PMID : 32835580






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells. alectinib ret proto-oncogene Homo sapiens
2 Although small molecule agents with RET kinase inhibitory activity such as alectinib, vandetanib, and cabozantinib have been clinically evaluated in RET-fusion-positive NSCLC, an effective monotherapy regimen has not been established. alectinib ret proto-oncogene Homo sapiens
3 We explored agents to use in combination with alectinib to enhance the antitumor effect of alectinib against RET-fusion cells. alectinib ret proto-oncogene Homo sapiens
4 We explored agents to use in combination with alectinib to enhance the antitumor effect of alectinib against RET-fusion cells. alectinib ret proto-oncogene Homo sapiens
5 Combination therapy with alectinib plus the CDK4/6 inhibitor enhanced the antitumor effect against RET-fusion-positive cells in vitro and in vivo. alectinib ret proto-oncogene Homo sapiens